focus -WSS

focus

author：Wikipedia 2025-10-01 14:15:38 - browse：46

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： In areas with more Black doctors, Black people live longer

explore

WSS

Why drug prescriptions should include diagnoses

WATCH: Why do fingernails fall off when they're damaged?

What it’s like to watch children die of measles

The strategy behind pharma's lawsuits over drug pricing reform

First medicine developed to treat MASH expected to be approved soon

The science behind Janet Jackson's pregnancy at 49

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Gene therapy has helped boys walk. Can scientists keep it that way?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Just how do doctors, lawmakers, and the public define abortion?

Anesthesiologist group: stop taking Ozempic before surgery

The story of mRNA: From a loose idea to a tool that may help curb Covid

Dobbs anniversary: the lost opportunity of abortion as health care

Why we need to separate burnout from moral injury in health care

At least 13 dead in Texas as scorching temps continue

Gene therapy has helped boys walk. Can scientists keep it that way?

Wikipedia

Change Healthcare payments predicted restored March 15

The problem with charging patients to message their doctors

Cloning humans is technically possible. It's curious no one has tried

The strategy behind pharma's lawsuits over drug pricing reform

The story of mRNA: From a loose idea to a tool that may help curb Covid

Former medical device CEO who sold dummy, plastic parts convicted of fraud

explore

Wikipedia

entertainment

leisure time